C-059
氯氮平标准液 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H19ClN4
化学文摘社编号:
分子量:
326.82
EC 号:
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24
等级
certified reference material
质量水平
表单
liquid
特点
SNAP-N-SPIKE®, SNAP-N-SHOOT®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
储存温度
−20°C
SMILES字符串
CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24
InChI
1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
InChI key
QZUDBNBUXVUHMW-UHFFFAOYSA-N
基因信息
human ... DRD2(1813), HTR2A(3356)
一般描述
经认证的Snap-N-Spike®溶液，用于通过LC/MS或GC/MS进行的临床毒理学，法医分析或尿液药物测试应用。氯氮平在美国以Clozaril®和FazaClo®出售，是一种非典型的抗精神病药物，用于精神分裂症的治疗。
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
FazaClo is a registered trademark of Jazz Pharmaceuticals International III Limited
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
储存分类代码
3 - Flammable liquids
WGK
WGK 2
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Bianca A Silva et al.
Nature neuroscience, 16(12), 1731-1733 (2013-11-12)
The neural circuits mediating fear to naturalistic threats are poorly understood. We found that functionally independent populations of neurons in the ventromedial hypothalamus (VMH), a region that has been implicated in feeding, sex and aggression, are essential for predator and
Saeko Ikai et al.
The Annals of pharmacotherapy, 47(7-8), e31-e31 (2013-06-13)
To report on a patient who was successfully rechallenged with clozapine after perforation of the large intestine and pulmonary embolism post operatively, and provide a literature review on clozapine rechallenge. A 46-year-old Japanese man with treatment-resistant schizophrenia developed constipation and
Benjamin W J Spencer et al.
Pharmacogenomics, 14(15), 1907-1914 (2013-11-19)
Clozapine is a uniquely efficacious antipsychotic drug in treatment-resistant schizophrenia. Its use is restricted due to adverse effects including a rare but dangerous reduction in neutrophils (agranulocytosis) and the mandatory hematological monitoring this entails in many countries. We review the
Rasmus Røge et al.
Schizophrenia research, 140(1-3), 204-213 (2012-07-27)
Clozapine remains the drug of choice for treatment resistant schizophrenia, but is associated with potentially life threatening side effects, including agranulocytosis and myocarditis. Immunological mechanisms may be involved in the development of these side effects or in the unique antipsychotic
Gary Remington et al.
Psychopharmacology, 225(3), 505-518 (2012-11-28)
Clozapine levels are advocated in the monitoring of patients on this drug and have now been used for a number of years. A safety-related threshold has also been proposed, as well as therapeutic lower and upper thresholds. While there has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持